• Criptomoedas
  • Mercados de Previsão
  • Notícias
  • Trading Agêntico
  • Artigos
  • Ligas

Pesquisar Criptomoedas

Criptomoedas em tendência

CoinRithm

Empresa

Entidade legal
Bees-x Limited
Número da empresa
13308136
Constituída em
England and Wales
Sede registrada
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm é um serviço de informação e pesquisa operado pela Bees-x Limited. Não é autorizado pela Financial Conduct Authority (FCA) a realizar atividades reguladas, e nada neste site constitui aconselhamento financeiro.

Explorar

CriptomoedasMercados de PrevisãoNotíciasArtigosAgent ArenaLigas

Recursos

Painel de ControleComércio SimuladoTrading AgênticoCarteiraLista de ObservaçãoConfigurações

Empresa

Sobre NósMetodologiaPara salas de aulaTermos de UsoPolítica de PrivacidadePolítica de CookiesAviso Legal

Suporte

Apoio ao ClienteFAQKit para desenvolvedoresDocumentação MCP

Redes Sociais

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Direitos reservados.
Disponível no Google PlayBaixar na App Store
  • Início
  • MercadosMercados de Previsão
  • Notícias
  • Painel de Controle
  1. Mercados de Previsão
  2. China
  3. FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
FDA decision: Ivonescimab by Summit Therapeutics (in 2026)

FDA decision: Ivonescimab by Summit Therapeutics (in 2026)

ChinaOne-OffHealth & Medicine6m
KalshiKalshiVerificar disponibilidadeKYC obrigatório2% de taxa
Probabilidade implícita atual
Sim
Sim 0%
Qualidade do mercado

24 / 100

Baixa qualidade
Volume 24h

0 €

Liquidez

0 €

Baixa liquidez
Compra / Venda

54.0% / 62.0%

Spread

14.8%

Spread amplo
Dados do mercado

Atualizado há 11 minutos

17/06/26, 21:001/01/27, 4:59

Tendências

Resultado24hProbabilidade
Sim
Sim
0%
Não
Não
100%

Resultado escolhido

Yes0%

Regras

If the FDA's decision on Ivonescimab by Summit Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Kalshi
  • This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
  • Ivonescimab (also called AK112 or SMT112) is a bispecific antibody — think of it as a single engineered drug molecule that carries two different "hooks" instead of one, allowing it to grab and block two disease-promoting proteins at the same time.
  • It was developed by Akeso and is being commercialized outside China by Summit Therapeutics.
  • By simultaneously neutralizing both targets, ivonescimab is designed to slow cancer growth more effectively than drugs that block only one pathway at a time.

Mercados Relacionados

Manifold Markets

Will China have more phase 3 drug trials than the United States in year X?

367,9 €
2026: 33%Manifold MarketsMANIFOLD MARKETS
Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

38,3 mil €
Sim: 4%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

5,9 mil €
Sim: 11%PolymarketPOLYMARKET
Measles cases in U.S. by June 30?

Measles cases in U.S. by June 30?

2,2 mil €
2150: 41%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

1,3 mil €
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Testosterone unscheduled/rescheduled more permissively in US by end of 2028?

994,7 €
Sim: 22.2%Manifold MarketsMANIFOLD MARKETS

Ativos nestes tópicos

BitcoinBTC$64,780.07-1.50%EthereumETH$1,762.10-1.75%SolanaSOL$72.60-1.38%DogecoinDOGE$0.0865-1.04%XRPXRP$1.19-1.99%BNBBNB$603.90-0.25%

Notícias Relacionadas

Chinese Man Gets 10+ Years for Stealing 107 BTC Using Memorized KeyBlockchain.NewsPentagon adds Alibaba, Baidu and BYD to China’s military-linked list Crypto NewsNvidia’s CEO declines Senate testimony on China’s AI chip businessCrypto NewsChina warns developers over overseas AI relay servicesCrypto NewsChina court treats Bitcoin as property in 107 BTC theft caseCrypto NewsChinese court treats Bitcoin as property in 107 BTC memory theft caseCointelegraph

Regras

If the FDA's decision on Ivonescimab by Summit Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Kalshi
  • This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
  • Ivonescimab (also called AK112 or SMT112) is a bispecific antibody — think of it as a single engineered drug molecule that carries two different "hooks" instead of one, allowing it to grab and block two disease-promoting proteins at the same time.
  • It was developed by Akeso and is being commercialized outside China by Summit Therapeutics.
  • By simultaneously neutralizing both targets, ivonescimab is designed to slow cancer growth more effectively than drugs that block only one pathway at a time.